JP2667193B2 - 二機能性タンパク質 - Google Patents

二機能性タンパク質

Info

Publication number
JP2667193B2
JP2667193B2 JP63093321A JP9332188A JP2667193B2 JP 2667193 B2 JP2667193 B2 JP 2667193B2 JP 63093321 A JP63093321 A JP 63093321A JP 9332188 A JP9332188 A JP 9332188A JP 2667193 B2 JP2667193 B2 JP 2667193B2
Authority
JP
Japan
Prior art keywords
asp
protein
thr
pro
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP63093321A
Other languages
English (en)
Japanese (ja)
Other versions
JPS63301898A (ja
Inventor
パウル、ハーバーマン
Original Assignee
ヘキスト、アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘキスト、アクチエンゲゼルシャフト filed Critical ヘキスト、アクチエンゲゼルシャフト
Publication of JPS63301898A publication Critical patent/JPS63301898A/ja
Application granted granted Critical
Publication of JP2667193B2 publication Critical patent/JP2667193B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP63093321A 1987-04-16 1988-04-15 二機能性タンパク質 Expired - Fee Related JP2667193B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873712985 DE3712985A1 (de) 1987-04-16 1987-04-16 Bifunktionelle proteine
DE3712985.6 1987-04-16

Publications (2)

Publication Number Publication Date
JPS63301898A JPS63301898A (ja) 1988-12-08
JP2667193B2 true JP2667193B2 (ja) 1997-10-27

Family

ID=6325799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63093321A Expired - Fee Related JP2667193B2 (ja) 1987-04-16 1988-04-15 二機能性タンパク質

Country Status (20)

Country Link
EP (1) EP0288809B1 (2)
JP (1) JP2667193B2 (2)
KR (1) KR970000187B1 (2)
AR (1) AR242991A1 (2)
AT (1) ATE79135T1 (2)
AU (1) AU613022B2 (2)
CA (1) CA1322157C (2)
DE (2) DE3712985A1 (2)
DK (1) DK170741B1 (2)
ES (1) ES2033981T3 (2)
FI (1) FI98830C (2)
GR (1) GR3006141T3 (2)
HU (1) HU204303B (2)
IE (1) IE61574B1 (2)
IL (1) IL86086A (2)
NO (1) NO176922C (2)
NZ (1) NZ224247A (2)
PH (1) PH25327A (2)
PT (1) PT87237B (2)
ZA (1) ZA882659B (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE69007975T2 (de) * 1989-08-22 1994-07-21 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) * 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
AU1551801A (en) * 1999-11-30 2001-06-12 Shionogi & Co., Ltd. Chemokine slc-il2 fused protein and gene thereof
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
WO2010001414A1 (en) * 2008-07-03 2010-01-07 Lupin Limited Expression of heterologous proteins in bacterial system using a gm-csf fusion tag

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8327880D0 (en) * 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
WO1985004673A1 (fr) * 1984-04-10 1985-10-24 Takeda Chemical Industries, Ltd. Nouvel adn et son utilisation
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
JPS61128889A (ja) * 1984-11-27 1986-06-16 Green Cross Corp:The 組換えｄｎａ及び該ｄｎａによる形質転換体
JPH0646957B2 (ja) * 1985-03-11 1994-06-22 武田薬品工業株式会社 インタ−ロイキン−２の製造方法
EP0238655A4 (en) * 1985-10-03 1989-09-11 Biogen Nv POLYPEPTIDES LIKE THE GRANULOCYTE-MACROPHOUS COLONY STIMULATION FACTORS (GM-CSF) AND THEIR METHODS OF PRODUCING LARGE QUANTITIES IN MICROBIAL CELLS.
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung

Also Published As

Publication number Publication date
PH25327A (en) 1991-04-30
NO881658D0 (no) 1988-04-15
AU1466188A (en) 1988-10-20
IL86086A (en) 1995-01-24
PT87237A (pt) 1988-05-01
AR242991A1 (es) 1993-06-30
HU204303B (en) 1991-12-30
PT87237B (pt) 1992-07-31
JPS63301898A (ja) 1988-12-08
NO176922B (no) 1995-03-13
FI881743A0 (fi) 1988-04-14
ZA882659B (en) 1988-10-14
KR970000187B1 (ko) 1997-01-06
ATE79135T1 (de) 1992-08-15
DE3873397D1 (de) 1992-09-10
IL86086A0 (en) 1988-09-30
DK209188D0 (da) 1988-04-15
FI98830C (fi) 1997-08-25
HUT47319A (en) 1989-02-28
AU613022B2 (en) 1991-07-25
FI98830B (fi) 1997-05-15
KR880012760A (ko) 1988-11-29
EP0288809B1 (de) 1992-08-05
IE881146L (en) 1988-10-16
DE3712985A1 (de) 1988-11-03
NZ224247A (en) 1990-04-26
CA1322157C (en) 1993-09-14
DK170741B1 (da) 1996-01-08
GR3006141T3 (2) 1993-06-21
NO176922C (no) 1995-06-21
DK209188A (da) 1988-10-17
EP0288809A1 (de) 1988-11-02
ES2033981T3 (es) 1993-04-01
IE61574B1 (en) 1994-11-16
NO881658L (no) 1988-10-17
FI881743L (fi) 1988-10-17

Similar Documents

Publication Publication Date Title
JP2667193B2 (ja) 二機能性タンパク質
US5359035A (en) Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
KR940005585B1 (ko) 과립구 대식세포 콜로니 촉진 인자(gm-csf)단백질의 제조방법
US5180811A (en) Proteins having a tnf action comprising tnf-fibromectin fusion protein
EP1194575B1 (en) Modified human granulocyte-colony stimulating factor and process for producing same
JP2000060577A (ja) 成熟ヒトインタ―ロイキン１タンパク質
JP3133305B2 (ja) 好中球活性化因子
WO1989001046A1 (en) Purification of human interleukin-4 expressed in escherichia coli
AU621051B2 (en) Method for purifying granulocyte-macrophage colony stimulating factor
JPS6312299A (ja) ポリペプチドの生産のための発現ベクタ−、ポリペプチドの交換発現法、発現ベクタ−を含有する宿主、それによりつくられた生産物
EP0423641A2 (en) Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or TGFalpha
EP0341100B1 (en) DNA coding for thymosin and TNF
JP2698976B2 (ja) 新規ポリペプチド及びそれをコードするｄｎａ
RU2048521C1 (ru) Способ получения полипептида со свойствами лимфотоксина человека
EP0213463B1 (en) Interleukin 2 receptor and a method for its production
RU2708556C1 (ru) Рекомбинантная плазмидная ДНК p280_2GM, кодирующая полипептид со свойствами гранулоцитарно-макрофагального колониестимулирующего фактора человека, штамм E.COLI SG 20050/ p280_2GM - продуцент полипептида со свойствами гранулоцитарно-макрофагального колониестимулирующего фактора человека и способ получения указанного полипептида
JP3786433B2 (ja) 均一なｎ末端を有する組換え型ヒトインターロイキン６及びその製造方法
JPH02177896A (ja) 新規生理活性ポリペプチド
JPH0482900A (ja) 新規ｍ―ｃｓｆ及びその製造方法
Gruber et al. Biochemical characterization of a novel autocrine transferrin-like growth factor in acute myeloblastic leukemia
JPH0728746B2 (ja) 新規プラスミド、微生物細胞及びヒト免疫グロブリンＧ Ｆｃ領域蛋白質の製造法
JPS63160598A (ja) 新規生理活性ポリペプチド
JPH0673095A (ja) ヒト インターロイキン１活性を有するポリペプチド
JPH0361495A (ja) 新規生理活性ポリペプチド
JPH0365195A (ja) 新規生理活性ポリペプチド

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees